other material
confidence high
sentiment positive
materiality 0.80
Batoclimab meets MG Phase 3 primary endpoint; CIDP shows 84% responder rate with >70% IgG reduction
Immunovant, Inc.
- MG Phase 3: 680mg batoclimab arm achieved 5.6-point MG-ADL improvement vs 3.6 placebo (p<0.001).
- Minimal Symptom Expression (MSE) at Week 12: 42% for 680mg, 31% for 340mg, 7% placebo.
- CIDP Phase 2b Period 1: 1.8-point aINCAT improvement; 84% responder rate among patients with ≥70% IgG reduction.
- Company will not seek batoclimab approval in MG/CIDP; focusing on IMVT-1402 and awaiting thyroid eye disease data.
- IND cleared for IMVT-1402 in MG and CIDP; registrational studies expected to start imminently.